Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy

Summary

In patients with at least moderate persistent allergic asthma controlled with inhaled steroids, omalizumab(administered per US product label), when compared to placebo, will provide the participants with significantly improved tolerability of specific allergen immunotherapy (allergy shots) administered per a cluster schedule(rapid build up method).

Timeline

Start

2006-05

Primary completion

2007-05

Completion

2007-10

Drugs

Indications